Evidence map›Paper›PMID 40056339›Full record

ArticleMolecular and cellular biochemistry2025

SKA3 promotes lung adenocarcinoma progression via the EGFR/E2F1/SKA3/integrin β1 signaling loop.

Xiufen Zheng, Zedong Sun, Shi Wang, Qibing Liu, Biqing Zhu, Zhijian Ren, Dingwei Fan, Chunping Zhang, Xinyin Fu, Yan Jin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiufen ZhengDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Zedong SunDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Shi WangDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Qibing LiuDepartment of Pharmacy, The First Affiliated Hospital of Hainan Medical University, Hainan, 570102, China.
Biqing ZhuDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Zhijian RenDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Dingwei FanDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China.
Chunping ZhangDepartment of Pharmacy, The First Affiliated Hospital of Hainan Medical University, Hainan, 570102, China.
Xinyin FuDepartment of Pharmacy, The First Affiliated Hospital of Hainan Medical University, Hainan, 570102, China.
Yan JinDepartment of Pharmacy, The First Affiliated Hospital of Hainan Medical University, Hainan, 570102, China.
Jing LuoDepartment of Cardiothoracic Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China. luojing_2767983@163.com.
Jie WangDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China. wangjie5204007@hotmail.com.
Binhui RenDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital and Nanjing Medical University Affiliated Cancer Hospital and Jiangsu Institute of Cancer Research, 42 Baiziting Road, Nanjing, 210009, China. renbinhui@jszlyy.com.cn.

Funding

Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Innovation Center CXZX202224National Natural Science Foundation of China 81902354National Natural Science Foundation of China 82002435National Natural Science Foundation of China 82103552National Natural Science Foundation of China 82172624Youth Cultivation Funding of the First Affiliated Hospital of Hainan Medical University HYYFYPY202003
6 · The paper itself

Abstract

Spindle and kinetochore-associated complex subunit 3 (SKA3) contributes to tumor growth and metastasis, but its specific roles have not been clearly elucidated. In this study, we found that SKA3 contributed to lung adenocarcinoma (LUAD) progression by interacting with integrin β1. The expression characteristics of SKA3 in LUAD patients were analyzed by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets and validated in 33 paired LUAD tissues by immunohistochemistry. Our data confirmed that SKA3 was a crucial regulator of LUAD progression and was associated with worse patient survival. In vitro and in vivo studies showed that SKA3 increased cell migration and invasion. Mechanistically, it was demonstrated that SKA3 could bind to integrin β1 and promote its activation, which further promoted the activation of EGFR. As a positive feedback loop, the activation of EGFR in turn promoted the expression of SKA3 via E2F1-mediated transcriptional regulation. Inhibition of EGFR with AZD9291 blocked SKA3 signaling induced by E2F1. These results indicated that SKA3 was crucial for the activation of EGFR and its downstream signaling pathway. Our findings uncovered the oncogenic role of SKA3 in LUAD progression and elucidated a novel EGFR/E2F1/SKA3/integrin β1 signaling loop, providing a potential SKA3-directed therapeutic strategy for LUAD patients.

Indexed as

Adenocarcinoma of LungCell Cycle ProteinsE2F1 Transcription FactorIntegrin beta1Lung NeoplasmsMicrotubule-Associated ProteinsSignal TransductionAnimalsCell Line, TumorCell MovementDisease ProgressionErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansMaleCell Cycle ProteinsE2F1 protein, humanE2F1 Transcription FactorEGFR protein, humanErbB ReceptorsIntegrin beta1Itgb1 protein, humanMicrotubule-Associated ProteinsSka3 protein, humanE2F1EGFRIntegrin β1Lung adenocarcinomaSKA3

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.